Powered by 
Technavio
miRagen Therapeutics Inc. | Data-Driven Analysis and Industry Review
Published: August 20, 2024MiRagen Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery and development of microRNA-based therapeutics. MicroRNAs are small non-coding RNAs that play a crucial role in regulating gene expression. MiRagen is utilizing its proprietary technology platform to develop miRNA mimics, which are designed to mimic the function of natural miRNAs in order to treat genetic diseases and cancers. The company's lead program, MRG-201, is a miR-29a mimic for the treatment of systemic sclerosis and other fibrotic diseases. MiRagen is also advancing a pipeline of preclinical programs in areas such as cardiovascular and liver diseases. The company is headquartered in Boulder, Colorado.'
1. Focused on the discovery and development of microRNA-based therapeutics for the treatment of fibrotic diseases, genetic diseases, and cancers.
2. Utilizes proprietary technology platform, miRagen Mimetics, to develop small RNA oligonucleotides that mimic the function of natural microRNAs, silencing disease-causing genes.
3. Leading clinical-stage biotech company with a pipeline of multiple product candidates, including MRG-201 for systemic sclerosis, MRG-110 for Duchenne muscular dystrophy, and MRG-152 for cancer.
4. Collaborations and partnerships with leading academic institutions, research organizations, and pharmaceutical companies to expand its pipeline and advance its research.
5. Experienced management team with a track record of successfully developing and commercializing innovative therapeutics, including the approval of the first microRNA-based therapeutic, Patisiran, by Alnylam Pharmaceuticals.
1. MiRagen Therapeutics is a clinical-stage biopharmaceutical company specializing in the discovery and development of microRNA-based therapeutics.
2. They utilize their proprietary technology platform, miRAGE™ (MicroRNA Analysis for Gene Expression), to identify and develop microRNA therapeutics for various diseases.
3. Their pipeline includes multiple programs in cardiovascular and fibrotic diseases, such as MRG-201 for systemic sclerosis and Duchenne muscular dystrophy.
4. MiRagen Therapeutics has entered into collaborations with pharmaceutical companies and academic institutions to expand their research and development capabilities.
5. The company is headquartered in La Jolla, California, and has a research facility in Boulder, Colorado.
Browse Our Research Portfolio In miRagen Therapeutics Inc. Markets
Health Care
Health Care
Health Care
Biotechnology and Life Sciences
Biotechnology and Life Sciences
Health Care Equipment & Supplies
Pharmaceuticals
Pharmaceuticals
Health Care Equipment
About Technavio
With unparalleled market insights, our research is designed to elevate your business to new heights. Technavio stands at the forefront of market research with a global perspective. Our approach is grounded in four key principles: accessible reports, comprehensive industry analysis, a focus on innovative and emerging technologies, and competitive pricing. We are dedicated to empowering companies and executives to make informed, timely, and strategic decisions.
